Phibro Animal Health Corporation (PAHC) Return on Investment ROI from the fourth quarter of 2026 to fourth quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Phibro Animal Health Corporation  (NASDAQ: PAHC)


Phibro Animal Health's ROI from its fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Phibro Animal Health's ROI in the fourth quarter of 2026?
Phibro Animal Health Corporation achieved a return on average invested assets (ROI) of 8.11 % in its fourth quarter of 2026, which is below Phibro Animal Health's average return on investment, which stands at 8.34%.

Despite the deterioration in its net income, company has improved ROI compared to the third quarter of 2026.

Within the Healthcare sector 92 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 1109, from total ROI ranking in the third quarter of 2026 at 1112.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
IV. Quarter		 (Mar 31 2026)
III. Quarter		 (Dec 31 2025)
II. Quarter		 (Sep 30 2025)
I. Quarter		 (Jun 30 2025)
IV. Quarter
Y / Y Investment Change TTM 24.78 % 47.42 % 62.09 % 46.82 % 31.74 %
Y / Y Net Income Change TTM 106.61 % 199.55 % 743.93 % 777.65 % 6318.09 %
Investment (TTM) in Millions 1,185 1,293 1,206 1,236 1,206
Return On Investment (TTM) 8.11 % 7.71 % 7.64 % 6.18 % 4.9 %
PAHC's Overall Ranking # 1109 # 1112 # 174 # 1089 # 1120
Seq. Investment Change TTM -0.44 % 2.56 % 9.76 % 11.34 % 17.63 %
Seq. Net Income Change TTM 4.71 % 3.41 % 35.79 % 40.51 % 51.81 %
Net Income (TTM) in Millions 100 95 92 68 48

PAHC Company Profile >> Back to PAHC Roi Comparisons >> See Annual PAHC Return On Investment



Return On Investment PAHC's Ranking
Within: No.
Industry # 33
Sector # 93
Overall # 1109

Return On Investment Statistics
High Average Low
18.81 %
8.34 %
-1.26 %
(Jun 30 2016)   (Jun 30 2014)







Financial Statements
Phibro Animal Health's IV. Quarter Investments $ 1,185 Millions PAHC's Balance sheet
Phibro Animal Health's IV. Quarter Income $ 22 Millions Quarterly PAHC's Income Statement
PAHC's Income by Division See PAHC's Income by Division


PAHC Annual Return On Investment (Jun 30 2026)
2026		 (Jun 30 2025)
2025		 (Jun 30 2024)
2024		 (Jun 30 2023)
2023		 (Jun 30 2022)
2022
Total Investments in Millions 1,185 1,067 778 795 741
Y / Y Investment Growth 10.99 % 37.2 % -2.18 % 7.36 % 9.4 %
Net Income in Millions 100 48 2 33 49
Y / Y Net Income Growth 106.61 % 1897.68 % -92.59 % -33.69 % -9.58 %
Annual Return On Investment 8.42 % 4.52 % 0.31 % 4.1 % 6.64 %


Annual Roi Comment
In the fiscal year 2026 ROI improved to 8.42 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
PAHC's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for PAHC's Competitors
Subscribers only: Roi for Phibro Animal Health's Suppliers
Subscribers only: Return On Investment for PAHC's Customers

Other Ratios
PAHC's Roa PAHC's Inventory Turnover Ratio PAHC's Growth Rates PAHC's Dividend Statistics
PAHC's Profitability Ratios PAHC's Asset Turnover Ratio PAHC's Dividend Growth
PAHC's Roe PAHC's Valuation Ratios PAHC's Financial Strength Ratios PAHC's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Agilent Technologies inc   19.84 %
Illumina Inc   19.61 %
Puma Biotechnology Inc   19.60 %
United Therapeutics Corporation  19.53 %
Zoetis Inc   19.44 %
Krystal Biotech Inc   19.16 %
Carlisle Companies Incorporated  18.88 %
Neurocrine Biosciences Inc   17.51 %
Intuitive Surgical Inc   17.11 %
Theravance Biopharma inc   17.10 %
Standard Biotools Inc   16.38 %
Inspire Medical Systems inc   16.34 %
Aveanna Healthcare Holdings Inc   16.32 %
Harmony Biosciences Holdings inc   15.85 %
Entera Bio Ltd   15.84 %
Nephros Inc   15.31 %
West Pharmaceutical Services Inc   15.29 %
Progyny Inc   15.25 %
Biolife Solutions Inc   14.83 %
Sbc Medical Group Holdings Incorporated  14.78 %
Spero Therapeutics Inc   14.54 %

Date modified: 2026-09-08T15:22:21+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.